CMS Plans Guidance On “Best Price”; GAO Urges More Oversight Of Rebates
Executive Summary
The Centers for Medicare & Medicaid Services plans to offer guidance to manufacturers on how contracts with pharmacy benefit management companies should be analyzed in calculating Medicaid rebates
You may also be interested in...
Medicare Rx Risk-Sharing Deals Not Covered By Safe Harbors, Attorneys Say
Drug manufacturers and Medicare Part D drug plan sponsors may be misinterpreting the Medicare Modernization Act as they form risk-sharing arrangements, Sidley Austin Brown & Wood Partner William Sarraille told the Pharmaceutical Compliance Summit March 30 in Philadelphia
Medicare Rx Risk-Sharing Deals Not Covered By Safe Harbors, Attorneys Say
Drug manufacturers and Medicare Part D drug plan sponsors may be misinterpreting the Medicare Modernization Act as they form risk-sharing arrangements, Sidley Austin Brown & Wood Partner William Sarraille told the Pharmaceutical Compliance Summit March 30 in Philadelphia
Distribution Fees Remain Concern In ASP Reporting Despite CMS Clarification
The Centers for Medicare & Medicaid Services' position that bona fide service fees paid by manufacturers to wholesalers are exempt from average sales price calculations may not resolve problems with the fee-for-service distribution model, Sidley Austin Brown & Wood attorney William Sarraille said